SI3347356T1 - Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors - Google Patents
Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitorsInfo
- Publication number
- SI3347356T1 SI3347356T1 SI201631188T SI201631188T SI3347356T1 SI 3347356 T1 SI3347356 T1 SI 3347356T1 SI 201631188 T SI201631188 T SI 201631188T SI 201631188 T SI201631188 T SI 201631188T SI 3347356 T1 SI3347356 T1 SI 3347356T1
- Authority
- SI
- Slovenia
- Prior art keywords
- derivatives
- tricyclic fused
- brd4 inhibitors
- pyridin
- fused pyridin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4781CH2015 | 2015-09-09 | ||
| EP16798006.9A EP3347356B1 (en) | 2015-09-09 | 2016-09-08 | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
| PCT/IN2016/050300 WO2017042834A1 (en) | 2015-09-09 | 2016-09-08 | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3347356T1 true SI3347356T1 (en) | 2021-08-31 |
Family
ID=57346000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631188T SI3347356T1 (en) | 2015-09-09 | 2016-09-08 | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10689395B2 (en) |
| EP (1) | EP3347356B1 (en) |
| JP (1) | JP6838052B2 (en) |
| KR (1) | KR102759651B1 (en) |
| CN (1) | CN108137588B (en) |
| AU (1) | AU2016319638B2 (en) |
| CA (1) | CA2997531A1 (en) |
| CY (1) | CY1124245T1 (en) |
| DK (1) | DK3347356T3 (en) |
| ES (1) | ES2866073T3 (en) |
| HR (1) | HRP20210581T1 (en) |
| HU (1) | HUE053912T2 (en) |
| IL (1) | IL257473B (en) |
| LT (1) | LT3347356T (en) |
| MX (1) | MX382128B (en) |
| PL (1) | PL3347356T3 (en) |
| PT (1) | PT3347356T (en) |
| RS (1) | RS61803B1 (en) |
| RU (1) | RU2734959C2 (en) |
| SI (1) | SI3347356T1 (en) |
| SM (1) | SMT202100277T1 (en) |
| WO (1) | WO2017042834A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| CN108472300A (en) | 2015-09-11 | 2018-08-31 | 达纳-法伯癌症研究所股份有限公司 | Cyano thiophene and triazol diazacyclo heptantriene and application thereof |
| KR20180051576A (en) * | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | Acetamide thienotriazolol diazepines and their uses |
| PE20181298A1 (en) | 2015-11-25 | 2018-08-07 | Dana Farber Cancer Inst Inc | BIVALENT BROMODOMINIUM INHIBITORS AND USES OF THEM |
| RU2019117356A (en) * | 2016-11-10 | 2020-12-10 | Лосинь Фармасьютикал (Шанхай) Ко., Лтд. | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, METHOD FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND APPLICATION |
| CN112119065B (en) * | 2018-07-13 | 2024-01-23 | 四川科伦博泰生物医药股份有限公司 | Benzodiazepine compound, preparation method and application thereof |
| CN119841849B (en) * | 2024-09-26 | 2025-08-15 | 浙江大学 | Pyridone compound, synthesis method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133288A1 (en) * | 2007-04-25 | 2008-11-06 | Daiichi Sankyo Company, Limited | Tricyclic aryl compounds |
| AU2010299820A1 (en) * | 2009-09-28 | 2012-04-19 | F. Hoffmann-La Roche Ag | Benzoxepin PI3K inhibitor compounds and methods of use |
| AR084070A1 (en) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | BROMODOMINIUM INHIBITORS AND USES OF THE SAME |
| TWI602820B (en) * | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | Bromodomain inhibitors and uses thereof |
| JP6419735B2 (en) * | 2013-03-12 | 2018-11-07 | アッヴィ・インコーポレイテッド | Tetracyclic bromodomain inhibitors |
| MX376112B (en) * | 2015-03-30 | 2025-03-07 | Jubilant Biosys Ltd | Tricyclic fused derivatives of 1-(cyclo)alkylpyridin-2-one as inhibitory compounds of the BET family of bromodomains, and their use in the treatment of proliferative disorders or cancer. |
-
2016
- 2016-09-08 HR HRP20210581TT patent/HRP20210581T1/en unknown
- 2016-09-08 CN CN201680060520.9A patent/CN108137588B/en active Active
- 2016-09-08 MX MX2018002738A patent/MX382128B/en unknown
- 2016-09-08 SI SI201631188T patent/SI3347356T1/en unknown
- 2016-09-08 WO PCT/IN2016/050300 patent/WO2017042834A1/en not_active Ceased
- 2016-09-08 RU RU2018112015A patent/RU2734959C2/en active
- 2016-09-08 HU HUE16798006A patent/HUE053912T2/en unknown
- 2016-09-08 CA CA2997531A patent/CA2997531A1/en active Pending
- 2016-09-08 PL PL16798006T patent/PL3347356T3/en unknown
- 2016-09-08 RS RS20210541A patent/RS61803B1/en unknown
- 2016-09-08 US US15/754,292 patent/US10689395B2/en active Active
- 2016-09-08 PT PT167980069T patent/PT3347356T/en unknown
- 2016-09-08 SM SM20210277T patent/SMT202100277T1/en unknown
- 2016-09-08 AU AU2016319638A patent/AU2016319638B2/en active Active
- 2016-09-08 EP EP16798006.9A patent/EP3347356B1/en active Active
- 2016-09-08 ES ES16798006T patent/ES2866073T3/en active Active
- 2016-09-08 LT LTEP16798006.9T patent/LT3347356T/en unknown
- 2016-09-08 DK DK16798006.9T patent/DK3347356T3/en active
- 2016-09-08 KR KR1020187009754A patent/KR102759651B1/en active Active
- 2016-09-08 JP JP2018511681A patent/JP6838052B2/en active Active
-
2018
- 2018-02-12 IL IL257473A patent/IL257473B/en unknown
-
2020
- 2020-05-11 US US16/872,309 patent/US11267820B2/en active Active
-
2021
- 2021-05-07 CY CY20211100393T patent/CY1124245T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251441A0 (en) | Imidazo pyridine derivatives and pharmaceutical compositions containing them | |
| IL257473A (en) | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors | |
| IL246140A0 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| HUE067779T2 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| IL253656A0 (en) | Substituted mono- and polyazanaphthalene derivatives and their use | |
| IL255444A0 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| IL263172A (en) | Tricyclic heterocyclic derivatives, their preparation and use | |
| IL250397A0 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| HUE057328T2 (en) | Aminopyridine derivatives and their use as selective alk-2 inhibitors | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| HUE038944T2 (en) | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors |